Background:

E3 ligase Ligand 2 is a Ligand for E3 Ligase used in PROTAC technology.

Thalidomide may exert anti-angiogenic effect in isolated blood vessels and endothelial cells. E3 ligase Ligand 2 is a putative hydroxylated thalidomide metabolite. E3 ligase Ligand 2 has weak anti-angiogenic activity (14% mean inhibition of blood vessel density at 100 mg). E3 ligase Ligand 2 does not have any anti-proliferative effect against the breast or neuroblastoma cells, but do possess appreciable anti-proliferative activity against the endothelial cells[1].

[1]. Marks MG, et al. Effects of putative hydroxylated thalidomide metabolites on blood vessel density in the chorioallantoic membrane (CAM) assay and on tumor and endothelial cell proliferation. Biol Pharm Bull. 2002 May;25(5):597-604.